UK markets open in 6 hours 13 minutes
  • NIKKEI 225

    27,616.91
    +333.32 (+1.22%)
     
  • HANG SENG

    25,961.03
    -354.27 (-1.35%)
     
  • CRUDE OIL

    73.60
    -0.35 (-0.47%)
     
  • GOLD FUTURES

    1,818.20
    +1.00 (+0.06%)
     
  • DOW

    34,935.47
    -149.03 (-0.42%)
     
  • BTC-GBP

    28,525.00
    -1,615.04 (-5.36%)
     
  • CMC Crypto 200

    957.40
    +7.50 (+0.79%)
     
  • ^IXIC

    14,672.68
    -105.62 (-0.71%)
     
  • ^FTAS

    4,030.24
    -23.88 (-0.59%)
     

Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH

·2-min read

Dermapharm Holding SE / Key word(s): Investment
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH

07-Jul-2021 / 16:39 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation, "MAR")

Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH

Grünwald, 7 July 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) today, via Dermapharm AG, entered into an agreement to acquire an equity investment and new shares in CORAT Therapeutics GmbH, Braunschweig, Germany. Upon the completion of the capital increase, Dermapharm AG acquires 24.9% of the shares in the company, which is developing an antibody drug for treating COVID-19. The drug, which would be used to treat hospitalised patients with moderate to severe symptoms of COVID-19, is currently undergoing testing in a clinical phase Ib/II trial. It has been shown to reduce the viral load (SARS-CoV-2) in the lungs by 99.4%. The parties have agreed to keep the purchase price for the shares confidential.

>End of ad hoc disclosure<

 

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
E-mail: ir@dermapharm.com

07-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany

Phone:

+49 (0)89 64 86-0

E-mail:

ir@dermapharm.com

Internet:

ir.dermapharm.de

ISIN:

DE000A2GS5D8

WKN:

A2GS5D

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

EQS News ID:

1216404


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting